Telix Appoints Paul Schaffer as Chief Technology Officer
News,
Telix today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today….
Read moreNews & Views
Anne Whitaker Appointed as Non-Executive Director
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April…
Read more
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
Telix today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the…
Read more
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telixtoday announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide…
Read more
Telix at EAU25
News,
Join Telix this week at Europe’s largest urological event, the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain. Telix’s Phase 3 ProstACT Global study of lead…
Read more
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in The Netherlands
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by MEB for the detection and…
Read more
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
Telix today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s…
Read more
Telix Adds Lead-212 Isotope Production Capability
News,
Telix today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first…
Read more
Telix Completes Acquisition of FAP-targeting Theranostic Candidates
Telix today announces that it has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in…
Read more
Patients Risk Missing Out on Revolution in Cancer Treatment: Report
Tens of thousands of Australians risk missing out on a new era of cancer treatment if Australia fails to fund and build the medical infrastructure needed to support it, according…
Read more